IMMUNIC, INC. Files 8-K for Material Definitive Agreement
Ticker: IMUX · Form: 8-K · Filed: Sep 3, 2024 · CIK: 1280776
| Field | Detail |
|---|---|
| Company | Immunic, INC. (IMUX) |
| Form Type | 8-K |
| Filed Date | Sep 3, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $33,987, $32,368 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, 8-k
TL;DR
IMMUNIC just signed a big deal, filing an 8-K. Details TBD.
AI Summary
On August 29, 2024, IMMUNIC, INC. entered into a material definitive agreement, the details of which are not fully disclosed in this filing. The company, incorporated in Delaware, operates in the Pharmaceutical Preparations sector and is headquartered in New York, NY.
Why It Matters
This filing indicates a significant business development for IMMUNIC, INC., potentially impacting its operations, partnerships, or financial standing.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, and the lack of specific details in this initial filing warrants a medium risk assessment.
Key Numbers
- 001-36201 — SEC File Number (Identifies the company's filing with the SEC.)
- 56-2358443 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- IMMUNIC, INC. (company) — Registrant
- August 29, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- New York, NY (location) — Principal executive offices address
- 2834 (sic_code) — Standard Industrial Classification for Pharmaceutical Preparations
FAQ
What is the nature of the material definitive agreement entered into by IMMUNIC, INC.?
The filing states that IMMUNIC, INC. entered into a material definitive agreement on August 29, 2024, but the specific terms and nature of the agreement are not detailed in this report.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on August 29, 2024.
In which state is IMMUNIC, INC. incorporated?
IMMUNIC, INC. is incorporated in Delaware.
What is IMMUNIC, INC.'s primary business sector?
IMMUNIC, INC. operates in the Pharmaceutical Preparations sector, indicated by its Standard Industrial Classification code 2834.
What is the principal executive office address for IMMUNIC, INC.?
The principal executive offices of IMMUNIC, INC. are located at 1200 Avenue of the Americas, Suite 200, New York, NY 10036.
Filing Stats: 498 words · 2 min read · ~2 pages · Grade level 9.8 · Accepted 2024-09-03 08:30:38
Key Financial Figures
- $0.0001 — ge on which registered Common Stock, $0.0001 par value IMUX The Nasdaq Stock Marke
- $33,987 — eased Dr. Nash's monthly base salary to $33,987 from $32,368 (which includes the cash r
- $32,368 — h's monthly base salary to $33,987 from $32,368 (which includes the cash retainer payab
Filing Documents
- e663859_8k-immunic.htm (8-K) — 20KB
- e663859_ex10-1.htm (EX-10.1) — 6KB
- 0001193805-24-001079.txt ( ) — 198KB
- imux-20240829.xsd (EX-101.SCH) — 3KB
- imux-20240829_lab.xml (EX-101.LAB) — 33KB
- imux-20240829_pre.xml (EX-101.PRE) — 22KB
- e663859_8k-immunic_htm.xml (XML) — 4KB
01. Entry into a Material Definitive Agreement
Item 1.01. Entry into a Material Definitive Agreement. On August 29, 2024, Immunic, Inc. (the "Company") and Dr. Duane Nash entered into Addendum Number 6 (the "Addendum") to the Employment Agreement dated April 17, 2020, as amended as of October 15, 2020, April 15, 2021, March 15, 2022, December 28, 2022 and October 17, 2023, to extend the term of Dr. Nash's employment as Executive Chairman of the Board of Directors of the Company (the "Board") to December 31, 2025. In connection with the Addendum, the Company increased Dr. Nash's monthly base salary to $33,987 from $32,368 (which includes the cash retainer payable for serving on the Company's Board or for acting as the Chairman of the Board). The Addendum is attached as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description of Exhibit 10.1 Addendum No. 6, dated August 29, 2024, to Employment Agreement, dated April 17, 2020, between Immunic, Inc. and Duane Nash.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. Dated: September 3, 2024 Immunic, Inc. By: /s/ Daniel Vitt Daniel Vitt Chief Executive Officer